elucidated the link between COVID-19 and TLRs, revealing upregulation of TLR4-mediated inflammatory signaling molecules and identifying S100A9 as a potential biomarker, offering insights into targeting TLR4-mediated inflammation therapeutically (54). This evidence concerns the gene TLR4 and COVID-19.